{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-180313","form_type":"8-K","ticker":"SLN","cik":"0001479615","company_name":"Silence Therapeutics plc","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.080681+00:00","generated_at":"2026-05-17T13:05:54.017015+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"Director Michael Davidson resigns from Silence Therapeutics board","bullets":["Davidson resigned as director effective August 11, 2025, citing need to focus on other time commitments.","He also stepped down from Audit, Risk, Remuneration, and Science & Technology Committees.","Board reduced from five to four members; Iain Ross appointed to Audit and Risk Committee.","Davidson remains CEO of NewAmsterdam Pharma; resignation not due to any disagreement with the Company."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-180313","json":"https://secwatch.observer/filing/0001193125-25-180313.json","markdown":"https://secwatch.observer/filing/0001193125-25-180313.md","text":"https://secwatch.observer/filing/0001193125-25-180313.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479615/000119312525180313/0001193125-25-180313-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479615/000119312525180313/d68551d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T13:05:54.017015+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}